Aggiornamento
Ma che fine fanno gli SGA?
What happens to SGA children? What could be done and it is not for children born small for gestational age without catch-up growth
Gianluca Tornese
SCU di Clinica Pediatrica, SS di Endocrinologia, Diabetologia e Altre Malattie del Metabolismo, IRCCS Materno-Infantile “Burlo Garofolo”, Trieste
Giugno 2019 - pagg. 355 -364
Abstract
Recombinant human growth hormone (rhGH) is an approved and effective treatment for
short children born small for gestational age (SGA). Prevalence of children eligible for treatment
as SGA is reported to be 1:1,800. The latest data from the Italian National Registry
of Growth Hormone therapy (RNAOC) showed that the number of children treated
with SGA indication is still small and these children are significantly less reported than those
treated for growth hormone deficiency (GHD), although GHD prevalence is 1:4,000-
1:10,000. This means that many short children born SGA are still not properly identified,
and therefore not treated with rhGH, or misdiagnosed as GHD. This article reviews indications
and benefits of rhGH treatment, reports some cases of treated children and provides
some practical tools for the identification of children eligible for rhGH treatment.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Contenuto riservato
Per leggere l'articolo completo è necessario effettuare il login.
Non sei ancora registrato? Registrati
Bibliografia
1. Soderling B. Pseudoprematurity. Acta Paediatr
1953;42(6):520-5.
2. Battaglia FC, Lubchenco LO. A practical
classification of newborn infants by weight
and gestational age. J Pediatr 1967;71(2):
159-63.
3. Lee PA, Chernausek SD, Hokken-Koelega
AC, Czernichow P; International Small for
Gestational Age Advisory Board. International
Small for Gestational Age Advisory Board
consensus development conference statement:
management of short children born
small for gestational age, April 24-October 1,
2001. Pediatrics 2003;111(6 Pt 1):1253-61.
4. Salomone R, Chiarelli F. Il bambino nato
piccolo per l’età gestazionale. Medico e Bambino
2007;26(6):363-9.
5. Alkalay AL, Graham JM Jr, Pomerance JJ.
Evaluation of neonates born with intrauterine
growth retardation: review and practice guidelines.
J Perinatol 1998;18(2):142-51.
6. Karlberg J, Cheung YB, Luo ZC. An update
on the update of growth charts. Acta Paediatr
1999;88:797-802.
7. Parazzini F, Cortinovis I, Bortolus R, et al.
Birth weight of infants born between the
23rd and 42nd gestational week in Italy. Pediatr
Med Chir 1998;20:93-7.
8. Gagliardi L, Macagno F, Pedrotti D, et al.
Standard antropometrici neonatali prodotti
dalla task-force della Società Italiana di Neonatologia
e basati su una popolazione italiana
Nord-Orientale. Riv Ital Ped 1999;25:159-69.
9. Bertino E, Murru P, Bagna R, et al. Anthropometric
neonatal standards based on a
north-west Italian population. Riv Ital Pediatr
1999; 25:899-906.
10. Vergara G, Carpentieri M, Colavita C. Birthweight
centiles in preterm infants. A new
approach. Minerva Pediatr 2002;54:221-5.
11. Festini F, Procopio E, Taccetti G, et al.
Birth weight for gestational age centiles for
Italian neonates. J Matern Fetal Neonatal
Med 2004; 15:411-7.
12. Polo A, Pezzotti P, Spinelli A, et al. Comparison
of two methods for constructing
birth weight charts in an Italian region: years
2000-2003. Epidemiol Prev 2007;31:261-9.
13. Bertino E, Spada E, Occhi L, et al. Neonatal
anthropometric charts: the Italian neonatal
study compared with other European studies.
J Pediatr Gastroenterol Nutr 2010;51
(3):353-61.
14. Italia. Determinazione dell’Agenzia Italiana
del Farmaco 19 giugno 2014. Modifica alla
Nota AIFA 39. Gazzetta Ufficiale. Serie Generale
n. 154 del 5 luglio 2014.
15. Raisanen S, Gissler M, Sankilampi U, Saari
J, Kramer MR, Heinonen S. Contribution
of socioeconomic status to the risk of small
for gestational age infants: A population-based
study of 1 390 165 singleton live births in
Finland. Int J Equity Health 2013;12:28.
16. Karlberg K, Albertsson-Wikland K.
Growth in full-term small-for-gestational-age
infants: from birth to final height. Pediatr Res
1995;38(5):733-9.
17. Fujita K, Nagasaka M, Iwatani S, et al.
Prevalence of small for gestational age (SGA)
and short stature in children born SGA who
qualify for growth hormone treatment at 3 years
of age: Population-based study. Pediatr
Int. 2016;58(5):372-6.
18. Leger J, Noel M, Limal JM, Czernichow
P. Growth factors and intrauterine growth retardation.
II. Serum growth hormone, insulin-
like growth factor (IGF) I, and IGF-binding
protein 3 levels in children with intrauterine
growth retardation compared with normal
control subjects: Prospective study from
birth to two years of age. Study Group of
IUGR. Pediatr Res 1996;40:101-7.
19. Karlberg JP, Albertsson-Wikland K,
Kwan EY, et al. The timing of early postnatal
catch-up growth in normal, full-term infants
born short for gestational age. Horm Res
1997;48 Suppl 1:17-24.
20. Albertsson-Wikland K, Karlberg J. Postnatal
growth of children born small for gestational
age. Acta Paediatr Suppl 1997;423:
193-5.
21. Albertsson-Wikland K, Karlberg J. Natural
growth in children born SGA with and without
catch up growth. Horm Res 2003;59
Suppl 1:129.
22. Clayton PE, Cianfarani S, Czernichow P,
et al. Management of the child born small for
gestational age through to adulthood: a consensus
statement of the International Societies
of Pediatric Endocrinology and the
Growth Hormone Research Society. J Clin
Endocrinol Metab 2007;92(3):804-10.
23. Gibson AT, Carney S, Cavazzoni E, et al.
Neonatal and postnatal growth. Horm Res
200;53(Suppl 1):42-9.
24. Hokken-Koelega AC, De Ridder MA,
Lemmen RJ, et al. Children born small for
gestational age: do they catch up? Pediatr
Res 1995;38(2):267-71.
25. de Ridder MA, Engels MA, Stijnen T, et
al. Small for gestational age children without
early catch-up growth: spontaneous growth
and prediction of height at 8 years. Horm
Res 2008;70(4):203-8.
26. Maiorana A, Cianfarani S. Impact of
growth hormone therapy on adult height of
children born small for gestational age. Pediatrics
2009;124:e519-31.
27. Jung H, Christof L, Nicolay C, et al.
Growth response to an individualized versus
fixed dose GH treatment in short children
born small for gestational age: the OPTIMA
study. Eur J Endocrinol 2009;160:149-56.
28. Dahlgren J, Kristrom B, Niklasson A, et
al. Models predicting the growth response to
growth hormone treatment in short children
independent of GH status, birth size and gestational
age. BMC Medical Informatics and
Decision Making 2007;7:40.
29. Dahlgren J, Albertsson-Wikland K. Final
height in short children born small for gestational
age treated with growth hormone. Pediatric
Research. 2005;57:216-22.
30. Chatelain P, Job JC, Blanchard J, et al.
Dose-dependent catch-up growth after 2 years
of growth hormone treatment in intrauterine
growth-retarded children. Belgian and
French Pediatric Clinics and Sanofi-Choay
(France). J Clin Endocrinol Metab 1994;78
(6):1454-60.
31. de Zegher F, Butenandt O, Chatelain P,
et al. Growth hormone treatment of short
children born small for gestational age: reappraisal
of the rate of bone maturation over 2
years and metanalysis of height gain over 4
years. Acta Paediatr Suppl 1997;423:207-12.
32. de Zegher F, Francois I, van Helvoirt M,
et al. Growth hormone treatment of short
children born small for gestational age.
Trends Endocrinol Metab 1998;9(6):233-7.
33. Italia. Determinazione dell’Agenzia del
Farmaco 22 settembre 2009. Modifica alla
Nota AIFA 39. Gazzetta Ufficiale - Serie generale
n. 238 del 13 ottobre 2009.
34. Renes JS, Willemsen RH, Wagner A, Finken
MJ, Hokken-Koelega AC. Bloom syndrome
in short children born small for gestational
age: a challenging diagnosis. J Clin Endocrinol
Metab 2013;98(10):3932-8.
35. Rose SR, Myers KC, Rutter MM, Mueller
R, Khoury JC, Mehta PA, Harris RE, Davies
SM. Endocrine phenotype of children and
adults with Fanconi anemia. Pediatr Blood
Cancer 2012;59(4):690-6.
36. Zhan-He Wu. The concept and practice of
Fanconi Anemia: from the clinical bedside to
the laboratory bench. Transl Pediatr 2013;
2(3):112-9.
37. Seminara S, Rapisardi G, La Cauza F, et.
al. Catch-up Growth in Short-at-birth NICU
Graduates. Horm Res 2000;53(3):139-43.
38. Simon D, Leger J, Carel JL. Optimal use
of growth hormone therapy for maximizing
adult height in children born small for gestational
age. Clin Endorinol Metab 2008;22(3):
525-37.
39. Carel JC, Chatelain P, Rochiccioli P, et al.
I mprovement in adult height after growth
hormone treatment in adolescents with short
stature born small for gestational age: results
of a randomized controlled study. J Clin Endocrinol
Metab 2003;88:1587-93.
40. Hokken-Koelega AC, van Pareren Y, Sas
T, et al. Final height data, body composition
and glucose metabolism in growth hormonetreated
short children born small for gestational
age. Horm Res 2003;60(Suppl 3):113-4.
41. van Pareren YK, Duivenvoorden HJ, Slijper
FS, et al. Intelligence and psychosocial
functioning during long-term growth hormone
therapy in children born small for gestational
age. J Clin Endocrinol Metab 2004;89:
5295-302.
42. de Bie HMA, Oostrom KJ, Delemarre-van
de Waal HA. Brain development, intelligence
and cognitive outcome in children born small
for gestational age. Horm Res 2010;73:6-14.
43. Saenger P, Czernichow P, Hughes I, et al.
Small for gestational age: short stature and
beyond. Endocr Rev 2007;28(2):219-51.
44. Leger J, Levy-Marchal C, Bloch J, et al.
Reduced final height and indications for insulin
resistance in 20 year olds born small for
gestational age: regional cohort study. BMJ
1997;315(7104):341-7.
45. Schweizer R, Martin DD, Schonau E, et
al. Muscle function improves during growth
hormone therapy in short children born
small for gestational age: results of a peripheral
quantitative computed tomography study
on body composition. J Clin Endocrinol Metab
2008;93:2978-83.
46. Sas T, Mulder P, Hokken-Koelega A. Body
composition, blood pressure, and lipid
metabolism before and during long-term
growth hormone (GH) treatment in children
with short stature born small for gestational
age either with or without GH deficiency. J
Clin Endocrinol Metab 2000;85:3786-92.
47. Arends NJ, Boonstra VH, Mulder PG, et
al. Growth hormone treatment and its effect
on bone mineral density, bone maturation
and growth in short children born small for
gestational age: 3-year results of a randomized,
controlled GH Trial. Clin Endocrinol
(Oxf) 2003;59(6):779-87.
48. Istituto Superiore di Sanità. Trattamento
con l’ormone somatotropo in Italia: rapporto
annuale del Registro Nazionale degli Assuntori
dell’Ormone della Crescita (2017). Pricci
F, Agazio E, Villa M (eds). 2018;3:102. Rapporti
ISTISAN 18/13.
49. Pricci F, Villa M, Maccari F, et al. The Italian
Registry of GH Treatment: electronic Clinical
Report Form (e-CRF) and web-based
platform for the national database of GH prescriptions.
J Endocrinol Invest 2018 Nov 15.
[Epub ahead of print].
50. Van den Berghe G, de Zegher F, Lauwers
P, Veldhuis JD. Growth hormone secretion
in critical illness: effect of dopamine. J Clin
Endocrinol Metab 1994;79(4):1141.
51. Dauber A, Rosenfeld RG, Hirschhorn JN.
Genetic Evaluation of Short Stature. J Clin
Endocrinol Metab 2014;99(9):3080-92.
52. Cacciari E, Milani S, Balsamo A, et al. Italian
cross-sectional growth charts for height,
weight and BMI (2 to 20 yr). J Endocrinol Invest
2006;29(7):581-93.
53. WHO Multicentre Growth Reference Study
Group. WHO Child Growth Standards based
on length/height, weight and age. Acta
Pædiatrica 2006;Suppl 450:76-85.
54. Toumba M, Albanese A, Azcona C, Stanhope
R. Effect of long-term growth hormone
treatment on final height of children with
Russell-Silver syndrome. Horm Res Paediatr
2010;74(3):212-7.
55. Azcona C, Stanhope R. Hypoglycaemia
and Russell-Silver syndrome. J Pediatr Endocrinol
Metab 2005;18(7):663-70.
56. Wakeling EL, Brioude F, Lokulo-Sodipe
O, et al. Diagnosis and management of Silver-
Russell syndrome: first international consensus
statement. Nat Rev Endocrinol 2017;
13(2):105-24.
Corrispondenza: gianluca.tornese@burlo.trieste.it